Predictive value of response to treatment of T-lymphocyte subpopulations in XXXX .

@entity1 @entity14047 @entity404 @entity1223 @entity19 @entity2416 @entity230 @entity405
T-cell types are important in maintaining immune homeostasis in the lung and their imbalance may be associated with several diseases. We examined the relationship between bronchoalveolar lavage (BAL) T-cell subset profiles and the clinical course of 46 @entity1 with @entity2416 ( @entity2416 ). A flow cytometry cell sorter (FACS) was used to analyse the T-cell subsets. Pulmonary function tests (PFT) were performed at baseline and 6-12 months later. @entity1 were divided into two groups according to their @entity404 / @entity405 ratio: @entity404 / @entity14047 (group 1, n=21); and @entity404 / @entity14047 (group 2, n=25). A lower percentage of lymphocytes, a higher percentage of @entity405 / @entity19 cells (cytotoxic T-lymphocytes) and a higher percentage of neutrophils were found in the BAL in group 2 compared to group 1 (11+/-7.5% versus 19+/-13.2%; p=0.024 and 29.8+/-17.6% versus 13.3+/-6.9%; p=0.068, respectively for lymphocytes and cytotoxic T-lymphocytes; and 8+/-11% versus 29+/-27%; p=0.003 for neutrophils). Inversely, in the peripheral blood, the distribution of @entity405 / @entity19 cells was lower in group 1 than in group 2 (8.3+/-6.9% versus 33.4+/-16.5%; p=0.0048). The @entity1 were followed over a period of 1 yr in order to test whether those findings could determine efficacy of therapy. The baseline transfer factor of the lung for @entity1223 (TL,CO) capacity in group 1 and group 2 was 59+/-22% and 51+/-21%, respectively (p=0.29), but only in group 1 was the TL,CO capacity improved significantly in response to @entity230 treatment after 6-12 months. @entity2416 @entity1 with a higher percentage of lymphocytes, a lower percentage of neutrophils, @entity404 / @entity405 >1 and a low percentage of @entity405 /S6F1 may have a more benign course of disease. These parameters may identify an early stage of reversible disease responsive to therapy. We conclude that these measurements may be a useful tool in monitoring response to treatment in @entity1 with @entity2416 .
